References
- Duchesne G. Prostate Cancer: Treating early-stage disease. Australian Oncology 2002; 5: 12–13
- Yeoh E, Botten R, Russo A, McGowan R, Fraser AC, Roos D, et al. Chronic effects of therapeutic irradiation for prostate carcinoma on anorectal function. Int J Radiat Oncol, Biol, Phys 2000; 47: 915–24
- Yeoh E, Fraser R, McGowan R, Botten R, DiMatteo AC, Roos D, et al. Evidence for efficacy without increased toxicity of hypofractionated radiation therapy for prostatic carcinoma; early results of a Phase III randomised trial. Int J of Radiat Oncol, Biol, Phys 2003; 55: 943–55
- Wu PM, Chua DT, Sham JS, Leung L, Kwong DL, Lo M, et al. Tumour control probability of nasopharyngeal carcinoma: a comparison of different mathematical models. Int J of Rad Oncol, Biol, Phys 1997; 37: 913–20
- Ragazzi G, Cattaneo GM, Fiorino C, Ceresoli G, Verusio C, Villa E, et al. Use of dose-volume histograms and biophysical models to compare 2D and 3D irradiation techniques for non-small cell lung cancer. Br Inst Radiol 1999; 72: 279–88
- Oh CE, Antes K, Darby M, Song S, Starkschall G. Comparison of 2D Conventional, 3D Conformal, Intensity Modulated Treatment Planning Techniques for patients with Prostate Cancer with regards to Target-Dose Homogeneity and Dose to Critical, Uninvolved Structures. Medical Dosimetry 1999; 24: 255–63
- Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet 1999; 353: 267–72
- Bey P. 3D-Conformal Radiation Therapy (3D-CRT) of prostate carcinoma. Cancer Radiotherapie 2000; 4(Supp1)113s–8s
- Di Matteo A, Botten R, Holloway R, Fraser R, Yeoh E. Persistent anorectal dysfunction is common despite 3D conformal radiation therapy for prostate carcinoma. J Gastroenterol Hepatol 2003; 18((Supp))B37
- Zelefsky MJ, Liebel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al. Dose Escalation with Three-Dimensional Conformal Radiation Therapy affects the Outcome in Prostate Cancer. Int J Radiat Oncol, Biol, Phys 1998; 41: 491–500
- Hanks GE, Hanlon AL, Schulteiss TE, Pinover WH, Movsas B, Epstein BE, et al. Dose Escalation with 3D Conformal Treatment: Five Year Outcomes, Treatment Optimisation, and Future Directions. Int J Radiat Oncol, Biol, Phys 1998; 41: 501–10
- Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate Cancer Dose Response: Results of the M.D. Anderson Phase III Randomised Trial. Int J Radiat Oncol, Biol, Phys 2002; 53: 1097–05
- Ten Kaken R, Foreman J, Heimburger D, Gerharsson A, McShan D, Perz-Tamayo C, et al. Treatment planning issues related to prostate movement in response to differential filling of rectal and bladder. Int J Radiat Oncol, Biol, Phys 1991; 20: 1317–24
- Vigneault E, Pouliot J, Laverdiere J, et al. Electronic portal imaging device detection of radioopaque markers for the evaluation of prostate position during megavoltage irradiation: a clinical study. Int J Radiat Oncol, Biol, Phys 1997; 37: 205–12
- Wu J, Haycocks T, Alasti H, Ottewell G, Middlemiss N, Abdolell M, et al. Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol 2001; 61: 127–33